Ardian-backed Neopharmed Gentili, an Italian pharmaceutical group , completed the acquisition of Valeas, a pharmaceutical company. Financial terms were not disiclosed. “The acquisition of Valeas represents a further step towards expanding our commitment in the neuropsychiatric area, where we are present with proven effective drugs for the treatment of anxiety disorders and insomnia, and towards consolidating our presence in respiratory and paediatrics, with a wide range of safe and effective products to meet the different needs of patients. The operation confirms and further strengthens our path of development and continuous growth to consolidate ourselves as an important Italian pharmaceutical company, also in an expansion phase at an international level," Alessandro Del Bono, Neopharmed Gentili CEO.